Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

BACKGROUND: Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Health (MoH) launched a campaign to immunise the 6·5 million residents of Israel aged 16 years and older. We estimat...

Descripción completa

Detalles Bibliográficos
Autores principales: Haas, Eric J, Angulo, Frederick J, McLaughlin, John M, Anis, Emilia, Singer, Shepherd R, Khan, Farid, Brooks, Nati, Smaja, Meir, Mircus, Gabriel, Pan, Kaijie, Southern, Jo, Swerdlow, David L, Jodar, Luis, Levy, Yeheskel, Alroy-Preis, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099315/
https://www.ncbi.nlm.nih.gov/pubmed/33964222
http://dx.doi.org/10.1016/S0140-6736(21)00947-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099315/
https://www.ncbi.nlm.nih.gov/pubmed/33964222
http://dx.doi.org/10.1016/S0140-6736(21)00947-8

Ejemplares similares